Zymeworks ROA 2016-2022 | ZYME
Current and historical return on assets (ROA) values for Zymeworks (ZYME) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Zymeworks ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2022-06-30 |
$-0.24B |
$0.37B |
-59.20% |
| 2022-03-31 |
$-0.24B |
$0.43B |
-56.34% |
| 2021-12-31 |
$-0.21B |
$0.39B |
-48.11% |
| 2021-09-30 |
$-0.21B |
$0.42B |
-44.17% |
| 2021-06-30 |
$-0.22B |
$0.47B |
-43.24% |
| 2021-03-31 |
$-0.20B |
$0.49B |
-35.34% |
| 2020-12-31 |
$-0.18B |
$0.54B |
-30.76% |
| 2020-09-30 |
$-0.22B |
$0.57B |
-39.38% |
| 2020-06-30 |
$-0.17B |
$0.61B |
-34.19% |
| 2020-03-31 |
$-0.16B |
$0.64B |
-35.60% |
| 2019-12-31 |
$-0.15B |
$0.37B |
-40.82% |
| 2019-09-30 |
$-0.06B |
$0.40B |
-19.74% |
| 2019-06-30 |
$-0.05B |
$0.42B |
-19.43% |
| 2019-03-31 |
$-0.03B |
$0.24B |
-13.53% |
| 2018-12-31 |
$-0.04B |
$0.24B |
-19.40% |
| 2018-09-30 |
$-0.01B |
$0.19B |
-7.99% |
| 2018-06-30 |
$-0.01B |
$0.21B |
-7.18% |
| 2018-03-31 |
$-0.02B |
$0.11B |
-13.02% |
| 2017-12-31 |
$-0.01B |
$0.13B |
-9.37% |
| 2017-09-30 |
$-0.05B |
$0.10B |
-55.53% |
| 2017-06-30 |
$-0.05B |
$0.12B |
-69.20% |
| 2017-03-31 |
$-0.05B |
$0.08B |
-105.75% |
| 2016-12-31 |
$-0.03B |
$0.09B |
-140.43% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.529B |
$0.412B |
|
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
|
